| Literature DB >> 35992360 |
Ana I Flores1, Caterina Pipino2, Urška Dragin Jerman3, Sergio Liarte4, Florelle Gindraux5,6, Mateja Erdani Kreft3, Francisco J Nicolas4, Assunta Pandolfi2, Larisa Tratnjek3, Bernd Giebel7, Michela Pozzobon8, Antonietta R Silini9, Ornella Parolini10,11, Günther Eissner12, Ingrid Lang-Olip13.
Abstract
Perinatal derivatives (PnD) are birth-associated tissues, such as placenta, umbilical cord, amniotic and chorionic membrane, and thereof-derived cells as well as secretomes. PnD play an increasing therapeutic role with beneficial effects on the treatment of various diseases. The aim of this review is to elucidate the modes of action of non-hematopoietic PnD on inflammation, angiogenesis and wound healing. We describe the source and type of PnD with a special focus on their effects on inflammation and immune response, on vascular function as well as on cutaneous and oral wound healing, which is a complex process that comprises hemostasis, inflammation, proliferation (including epithelialization, angiogenesis), and remodeling. We further evaluate the different in vitro assays currently used for assessing selected functional and therapeutic PnD properties. This review is a joint effort from the COST SPRINT Action (CA17116) with the intention to promote PnD into the clinics. It is part of a quadrinomial series on functional assays for validation of PnD, spanning biological functions, such as immunomodulation, anti-microbial/anti-cancer activities, anti-inflammation, wound healing, angiogenesis, and regeneration.Entities:
Keywords: amniotic epithelial cells; amniotic membrane; angiogenesis; functional assays; inflammation; mesenchymal stromal cells; perinatal derivatives; wound healing
Year: 2022 PMID: 35992360 PMCID: PMC9386263 DOI: 10.3389/fbioe.2022.965006
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Functional tests on perinatal cells.
|
| |||
|---|---|---|---|
|
|
|
|
|
| hAFSC | Establishment of skin equivalent | hAFSC differentiated into keratinocytes expressing K5, K14, K10, and involucrin after 30 days of culture in a keratinocyte-inducing medium and formed a complete pluristratified skin epithelium under air-liquid culture conditions on a collagen matrix with integrated HDF. | ( |
| hAMSC | Cell adhesion on a scaffold | hAMSC were grown on Matriderm and PCL/PLA scaffolds. PCL/PLA yielded a higher number of attached cells and more favorable growing conditions for hAMSC than Matriderm. | ( |
| hUC-MSC | (i) Cell proliferation assay | c-Jun silencing in hUC-MSC inhibited (i) cell proliferation and (ii) migration, while c-Jun overexpression enhanced proliferation but not migration of hUC-MSC. | ( |
| (ii) Scratch wound assay | |||
| Cell differentiation assay | hUC-MSC were transfected with a lentivirus expressing HOXA4 and cultured for 21 days. Expression of the epidermal cell-specific markers, cytokeratins 14 and 18, was detected by immunohistochemistry and flow cytometry. | ( | |
| Establishment of skin equivalent | hUC-MSC were seeded on the surface of fibrin gel scaffolds and cultured for 7–10 days. The established equivalent resembled the normal skin architecture. | ( | |
| (i) Cell proliferation assay | (i-iii) SAP improved the survival, proliferation, and migration of the hUC-MSC encapsulated in Pluronic F-127 hydrogel (drug delivery scaffold). | ( | |
| (ii) Cell viability assay | |||
| (iii) Scratch wound assay | |||
| (i) Cell proliferation | (i, ii) Activation of the Wnt signaling pathway promoted survival of hUC-MSC (proliferation, viability) seeded on a CCLDADM scaffold. (iii) Cells attached and grew uniformly when seeded onto the CCLDADM scaffold. | ( | |
| (ii) Cell viability assay | |||
| (iii) Cell adhesion on a scaffold | |||
| (i) Cell proliferation assay | 455-nm blue light exposure effectively promoted (i) proliferation, (ii) migration, and (iii) tube formation of HUVEC co-cultured with hUC-MSC. | ( | |
| (ii) Scratch wound assay | |||
| (iii) Tube formation assay | |||
| Chemotaxis assay | hUC-MSC seeded in 3D alginate gel gradually migrated from the top to the bottom of the gel, but could not migrate out from the gel during 7 days of observation. | ( | |
| Soft agar tumorigenicity test | Even after repeated passaging the cells have not acquired tumor formation capabilities. | ( | |
| a) hUC-MSC | (i) Cell proliferation assay | hUC-MSC-End showed increased (i) proliferation, (ii) migration and (iii) vasculogenesis compared to hUC-MSC. | ( |
| b) hU-MSC-End | (ii) Chemotaxis assay | ||
| (iii) CAM assay | |||
| hPMSC | Transwell co-culture assay | Co-culturing of hPMSC with HDF inhibited LPS-induced activation of NF-ĸB signal in HDF. | ( |
| Chemotaxis assay | hPMSC expressing PDGFR-β exhibited enhanced chemotactic migration compared to hPMSC without expressing PDGFR-β. | ( | |
| a) hAEC b) hUC-MSC | Cell differentiation assay | hAEC and hUC-MSC were able to differentiate into keratinocytes and fibroblasts, respectively, after 15 days of culturing in an inducing medium. This was shown by the expression of various specific markers by immunolabeling and RT-PCR. | ( |
Abbreviations: CCLDADM: collagen–chitosan laser drilling acellular dermal matrix, hAEC: human amniotic membrane epithelial cells, hAFSC: human amniotic fluid stem cells, hAMSC: human amniotic membrane mesenchymal stromal cells, HDF: human dermal fibroblasts, hPMSC: human placenta mesenchymal stromal cells, hUC-MSC: human umbilical cord mesenchymal stromal cells, hU-MSC-End: human umbilical cord mesenchymal stromal cells -endothelial transdifferentiated, HUVEC: human umbilical cord vein endothelial cells, LPS: lipopolysaccharides, NF-ĸB: nuclear factor kappa-light-chain-enhancer of activated B-cells, PCL/PLA: Poly(caprolactone)/poly(l-lactide), PDGFR-β: platelet derived growth factor receptor β, SAP: sodium ascorbyl phosphate.
Functional tests on perinatal tissue extracts alone or combined with conditioned medium (CM).
|
| |||
|---|---|---|---|
|
|
|
|
|
| hAM extract | (i) Cell apoptosis assay | (i) Higher concentrations of hAM extract increased the percentage of apoptotic and necrotic HDF. (ii, iii) hAM extract promoted HDF proliferation and migration. | ( |
| (ii) Cell proliferation assay | |||
| (iii) Scratch wound assay | |||
| Placental laminin | (i) Cell differentiation assay | (i) Placental laminin purified from hP extract promoted neuronal differentiation of neuronal cell line PC12 (ii) Non-toxic concentration of placental laminin for PC12 cell treatment was determined (0.17 lg/ml). (iii) Placental laminin accelerated migration and motility of mouse embryonic fibroblasts. (iv) Blocking of integrin receptor retarded neurite outgrowth in laminin treated PC12 cells. | ( |
| (ii) Cell viability assay | |||
| (iii) Scratch wound assay | |||
| (iv) Receptor antagonist assay | |||
| a) hAM powder | (i) Biocompatibility assay | (i) Heparinized human blood biocompatibility assay showed intact blood cells upon incubation with hAM powder or hAM powder + AV gel. (ii, iii) Media containing hAM powder + AV gel promoted HaCaT and HDF cell attachment and proliferation. (iv) hAM powder + AV significantly accelerated migration of HaCaT. | ( |
| b) hAM powder + AV | (ii) Cell attachment assay | ||
| (iii) Cell proliferation assay | |||
| (iv) Scratch wound assay | |||
| Solubilized hAM | (i) Cell proliferation assay | (i) hAM-hyaluronic acid hydrogel accelerated proliferation of HDF and keratinocytes compared to controls. (ii) Keratinocytes and HDF remained viable following hAM-hyaluronic acid hydrogel encapsulation. | ( |
| (ii) Cell viability assay | |||
| hWJ-ECM | (i) Cell proliferation assay | (i) The HDF cell line HSF-PI 18 attached to, infiltrated into and proliferated on hWJ-ECM scaffolds. (ii) hWJ-ECM was not cytotoxic. | ( |
| (ii) Cytotoxicity assay | |||
| hWJ-ECM | (i) Cell differentiation assay | (i) hWJ-ECM promoted differentiation of HDF into myofibroblasts (confirmed by upregulation of α-SMA expression). (ii) hWJ-ECM treatment did not affect cell proliferation or (iii) cell viability of HDF. (iv) hWJ-ECM enhanced HDF migration. | ( |
| (ii) Cell proliferation assay | |||
| (iii) Cell viability assay | |||
| (iv) Scratch wound assay | |||
Abbreviations: α-SMA: alpha-smooth muscle actin, AV: aloe vera, HaCaT: immortalized human keratinocytes, hAM: human amniotic membrane, hAMSC: human amniotic mesenchymal stromal cells, HDF: human dermal fibroblasts, hEK: human epidermal keratinocytes, hP: human placenta, hP-ECM: human placenta extracellular matrix, hUC-WJ-ECM: human umbilical cord Wharton´s jelly extracellular matrix.
FIGURE 1Perinatal derivatives and in vitro functional assays used for cutaneous wound healing in animals (A) The schematic presentation of PnD functionally tested in vitro and (B) frequency of use of in vitro functional assays in animal studies of cutaneous wound healing. The most frequently used functional assays are highlighted in blue.
Functional tests on perinatal cell-conditioned medium (CM) alone or compared to/or combined with perinatal cells.
|
| |||
|---|---|---|---|
|
|
|
|
|
| hAEC-CM | scratch wound assay | hAEC-CM substantially accelerated the migration of HDF. | ( |
| hPMSC-CM | (i) Cell proliferation assay | Hypoxic hPMSC-CM inhibited the (i) proliferation and (ii) migration of HDF compared to normal medium and normoxic CM. | ( |
| (ii) Scratch wound assay | |||
| hUC-MSC-CM | (i) Cell cycle analysis | (i) hUC-MSC-CM caused a G0/G1-phase cell cycle arrest of HUVEC. (ii) HUVEC treated with hUC-MSC-CM had a significantly down-regulated expression of genes for IFN, TNF, IL-1, and IL-6, while the key genes involved with angiogenesis (VEGF, EGF, bFGF, and KDR) were up-regulated. (iii) hUC-MSC-CM significantly increased the proliferation of HUVEC. | ( |
| (ii) Cell differentiation assay | |||
| (iii) Cell proliferation assay | |||
| Cytotoxicity assay | 50 and 100% ( | ( | |
| hAMSC-CM | (i) Scratch wound assay | (i) hAMSC-CM significantly increased the migration rate of HDF and HUVEC. (ii) HUVEC treated with hAMSC-CM formed significantly longer tubes compared to untreated controls. | ( |
| (ii) Tube formation test | |||
Abbreviations: bFGF: basic fibroblast growth factor, CAM: chick chorio allantoic membrane, CM: conditioned medium derived from hAEC, hAMSC, hPMSC, hUC-MSC, hUC-MSC-End, EGF: epidermal growth factor, HaCAT: immortalized human keratinocytes, hAEC: human amniotic membrane epithelial cells, hAMSC: human amniotic membrane mesenchymal stromal cells, HDF: human dermal fibroblasts hPMSC: human placenta mesenchymal stromal cells, hUC-MSC: human umbilical cord mesenchymal stromal cells, hU-MSC-End: human umbilical cord mesenchymal stromal cells-endothelial transdifferentiated, HUVEC: human umbilical cord vein endothelial cells, IL-1, IL-6: interleukin-1, -6, KDR: kinase insert domain receptor, PGE2: prostaglandin E2, TNF: tumor necrosis factor, VEGF: vascular endothelial cell growth factor. Perinatal cell-conditioned medium (CM).
Functional tests on Perinatal cell-derived small extracellular vesicles (sEV) alone or compared to perinatal cell-conditioned medium (CM).
|
| |||
|---|---|---|---|
|
|
|
|
|
| hUC-MSC-sEV | (i) Cell differentiation assay | (i) hUC-MSC-sEV inhibited α-SMA and collagen I and III expression in HDF cultivated at high cell density. (ii) hUC-MSC-sEV restrict HaCaT and HDF proliferation at high cell densities, but promote cell proliferation at low densities. | ( |
| (ii) Cell proliferation assay | |||
| (i) Cell proliferation assay | hUC-MSC-sEV promoted the (i, ii) proliferation, (iii, v) migration, and (iv) tube formation of a HUVEC-derived cell line in a dose-dependent manner. | ( | |
| (ii) Cytotoxicity assay | |||
| (iii) Scratch assay | |||
| (iv) Tube formation assay | |||
| (v) Chemotaxis assay | |||
| (i) Cell proliferation assay | hUC-MSC-sEV promoted (i) the proliferation, (ii) migration and (iii) tube-formation of HUVEC. hUC-MSC-sEV contained Ang-2, and treatment with hUC-MSC-sEV enhanced the expression of the Ang-2 in HUVEC through exosome-mediated Ang-2 transfer. | ( | |
| (ii) Chemotaxis assay | |||
| (iii) Tube Formation Assay | |||
|
| |||
|
|
|
|
|
| a) hUC-MSC-sEV | (i) Cell apoptosis assay | hUC-MSC-CM and hUC-MSC-sEV (i) decreased H2O2-induced cell apoptosis of HaCaT by inhibiting AIF and upregulating PARP-1 and poly ADP-ribose, (ii) increased HaCaT proliferation, in contrast to hUC-MSC-sEV-dp. (iii) hUC-MSC-CM improved the viability of HaCaT. (iv, vi) hUC-MSC-sEV and hUC-MSC-CM promoted cell migration relative to the hUC-MSC-sEV-dp. (vi) (v) ROS intensity in the hUC-MSC-sEV group and hUC-MSC-CM group was lower than in the control group. | ( |
| b) hUC-MSC-CM | (ii) Cell proliferation assay | ||
| (iii) Cell viability assay | |||
| (iv) Chemotaxis assay | |||
| (v) ROS generation assay | |||
| (vi) Scratch wound assay | |||
| (i) Cell proliferation assay | (i) hUC-MSC-sEV/Pluronic F-127 hydrogel promoted HUVEC proliferation better than hUC-MSC-sEV and hUC-MSC-CM. (ii) hUC-MSC-sEV and CM groups showed greater cell migration than the Pluronic F-127 hydrogel and control group. The hUC-MSC-sEV/Pluronic F-127 hydrogel group exhibited the best performance. | ( | |
| (ii) Scratch wound assay | |||
| a) hDMSC-sEV | Cell cycle assay Cell differentiation assay Cell proliferation assay Scratch wound assay Senescence assay ROS generation assay | (i) hDMSC-sEV enhanced proliferation of HG aged HDF, (iv) increased their migration rate, (ii) promoted differentiation of HG-aged HDF into myofibroblasts (increased α-SMA and collagen I protein expression), (v) inhibited senescence associated β-galactosidase expression and (vi) inhibited ROS generation in HG aged HDF. hDMSC-CM improved (iii) proliferation and (iv) migration of HDF. The sEV blocker GW4869 reduced both effects, indicating that hDMSC-sEV in hDMSC-CM probably enhance the proliferation and migration abilities of HDF. | ( |
| b) hDMSC-CM | |||
Abbreviations; Ang-2: angiopoietin-2, AIF: apoptosis-inducing factor, α-SMA: alpha-smooth muscle actin, CM: conditioned medium derived from hDMSC, hUC-MSC, HaCAT: immortalized human keratinocytes, HDF: human dermal fibroblast, hDMSC: human decidua mesenchymal stromal cells, HG: high glucose, hUC-MSC: human umbilical cord mesenchymal stromal cells, PARP-1: poly ADP, ribose polymerase 1, ROS: reactive oxygen species, sEV: small extracellular vesicles derived from hDMSC, hUC-MSC, sEV-dp: conditioned medium depleted from small extracellular vesicle. Perinatal cell-derived small extracellular vesicles (sEV).
Functional tests on perinatal tissues.
|
| |||
|---|---|---|---|
|
|
|
|
|
| Dehydrated hAM/chorion (EpiFix®) | (i) Cell proliferation assay | (i) Dehydrated hAM/chorion extracts caused a dose-dependent increase in HDF proliferation. (ii) Dehydrated hAM/chorion tissue allografts promoted migration of hMSC. (iii) Growth factors such as EGF, bFGF and TGF-1 were able to elute from dehydrated hAM/chorion into the saline. | ( |
| (ii) Chemotaxis assay | |||
| (iii) ELISA assay | |||
| Dehydrated hAM/chorion (EpiFix®) | (i) Cell proliferation assay | (i) Dehydrated hAM/chorion extract promoted HMVEC proliferation. (ii) Dehydrated hAM/chorion tissue recruited migration of HUVEC. (iii) Dehydrated hAM/chorion extract increased endogenous production of over 30 angiogenic factors by HMVEC, including GM-CSF, angiogenin, TGF-β3, and HB-EGF Heparin-binding EGF-like growth factor. | ( |
| (ii) Chemotaxis assay | |||
| (iii) ELISA assay | |||
| hAM | Cytotoxicity assay | Decellularized hAM enhanced the viability of hUC-MSC seeded onto the epithelial surface of hAM. | ( |
Abbreviations: bFGF: basic fibroblast growth factor, EGF: epidermal growth factor, GM-CSF: granulocyte macrophage colony-stimulating factor, hAM: human amniotic membrane, HB-EGF: Heparin-binding EGF-like growth factor, hMSC: human mesenchymal stromal cells, HMVEC: human microvascular endothelial cells, hUC-MSC: human umbilical cord mesenchymal stromal cells, TGF-1: transforming growth factor 1, TGF-β3: transforming growth factor β3.
FIGURE 2Schematic presentation of the major in vitro functional assays performed to validate the mechanisms of action of perinatal derivatives (PnD) in the context of inflammation, angiogenesis and remodeling during the complex process of wound healing. The figure was created using Biorender.com.